The clinical and financial impact of oral triptans - an updated meta-analysis

References

• Belsey JD. The clinical and financial impact of oral triptans in the management of migraine in the UK: a systematic review. Journal of Medical Economics 2000; 3: 35–47.
   Google Scholar
• Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. European Neurology 1991; 31: 295–299.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Bousser MG, Solomon S. Guidelines for controlled trials of drugs in migraine, 1st edn. 1991: 111–133.
   Google Scholar
• The Cochrane Collaboration. RevMan 4.1 User guide: Appendix K - Statistical methods used in MetaView. Oxford 2000; pp 71–76.
   Google Scholar
• Shøftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician’s view. Cephalalgia 2000; 20 (Suppl. 2): 14–24.
   Google Scholar
• Monthly Index of Medical Specialities. London: Haymarket Publishing, February 2002.
   Google Scholar
• Cook RJ, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal 1995; 310: 452–454.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials 1996; 17: 1–12.
   Google Scholar
• Geraud G, Oleson F, Pfaffenrath V et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000; 20: 30–38.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Teall J, Rodriguez F et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998; 38: 748–755.
   PubMed Web of Science ®Google Scholar
• Nappi G, Sicuteri F, Byrne M et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. Journal of Neurology 1994; 241: 138–144.
   PubMed Web of Science ®Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998; 38: 184–190.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J et al. Eletriptan in acute migraine: a double- blind, placebo-controlled comparison to sumatriptan. Neurology 2000; 54: 156–163.
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995; 346: 923–926.
   PubMed Web of Science ®Google Scholar
• Oral Sumatriptan International Multiple- Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. European Neurology 1991; 31: 306–313.
   PubMed Web of Science ®Google Scholar
• Visser WH, Terwindt GM, Reines SA et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo- controlled, dose-ranging study. Archives of Neurology 1996; 53: 1132–1137.
   PubMed Web of Science ®Google Scholar
• Cutler N, Mushet GR, Davis R et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995; 45: S5–S9.
   Web of Science ®Google Scholar
• Myllyla VV, Havanka H, Herrala L et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double- blind, randomized, controlled, parallel- group study. Headache 1998; 38: 201–207.
   PubMed Web of Science ®Google Scholar
• Savani N, Brautaset NJ, Reunanen M et al. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50 mg sumatriptan tablets in the acute treatment of migraine. International Journal of Clinical Practice 1999; (Suppl 105): 7–15.
   Google Scholar
• Teall J, Tuchman M, Cutler N et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998; 38: 281–287.
   PubMed Web of Science ®Google Scholar
• Pascual J, Vega P, Diener H-C et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 2000; 20: 455–461.
   PubMed Web of Science ®Google Scholar
• Kramer MS, Matzura-Wolfe D, Polis A et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998; 51: 773–781.
   Google Scholar
• Ahrens SP, Farmer MV, Williams DL et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999; 19: 525–530.
   PubMed Web of Science ®Google Scholar
• Bomhof M, Paz J, Legg N et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. European Neurology 1999; 42: 173–179.
   PubMed Web of Science ®Google Scholar
• Gijsman H, Kramer MS, Sargent J et al. Double-blind, placebo-controlled, dose- finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647–651.
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multicentre, double-blind, placebo-controlled, dose range-finding study. Neurology 1997; 49: 1210–1218.
   PubMed Web of Science ®Google Scholar
• Solomon GD, Cady RK, Klapper JA et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997;49:1219–1225.
   PubMed Web of Science ®Google Scholar
• Dahlof C, Diener H-C, Goadsby PJ et al. Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. European Journal of Neurology 1998; 5: 535–543.
   PubMed Web of Science ®Google Scholar
• Visser WH, Klein KB, Cox RC et al. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996; 46: 522–526.
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomised, double-blind, placebo- controlled study. Cephalalgia 2000; 20: 588–596.
   PubMed Web of Science ®Google Scholar
• Dodick, DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache 2002; 42: 21–27.
   PubMed Web of Science ®Google Scholar
• Dahlof C, Tfelt-Hansen P, Massiou H et al. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001; 57: 1811–1817.
   PubMed Web of Science ®Google Scholar
• Smith LA, Oldman AD, McQuay HJ, Moore RA. Eletriptan for acute migraine (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software, 2002.
   Google Scholar
• Department of Health Statistics Division. Prescription Cost Analysis England 2001. http://www.doh.gov.uk/stats/pca2001 .htm. Accessed 08.05.02
   Google Scholar
• Gobel H, Heinze A, Heinze-Kuhn K et al. Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70,527 patient episodes. Headache 2001; 41: 264–270.
   PubMed Web of Science ®Google Scholar
• Pascual J, Fité B, López-Gil A. Comparison of triptan tablet consumption per attack: a prospective study of migraineurs in Spain. Headache 2002; 42: 93–98.
   PubMed Web of Science ®Google Scholar
• Ferrari MD, Roon KI, Lipton RB et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta- analysis of 53 trials. Lancet 2001; 358: 1668–1675.
   PubMed Web of Science ®Google Scholar
• Adelman JU, Lipton RB, Ferrari MD et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001; 57: 1377–1383.
   PubMed Web of Science ®Google Scholar